Dynamic Technology Lab Private Ltd Sells 8,512 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Dynamic Technology Lab Private Ltd lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 82.7% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,781 shares of the medical research company's stock after selling 8,512 shares during the period. Dynamic Technology Lab Private Ltd's holdings in IQVIA were worth $422,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. First Foundation Advisors lifted its holdings in IQVIA by 3.8% in the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company's stock valued at $245,000 after acquiring an additional 43 shares during the period. Invera Wealth Advisors LLC boosted its holdings in shares of IQVIA by 0.3% in the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company's stock worth $3,183,000 after buying an additional 46 shares during the last quarter. Oregon Public Employees Retirement Fund grew its position in IQVIA by 0.3% during the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company's stock valued at $3,313,000 after buying an additional 48 shares during the period. Continuum Advisory LLC raised its position in IQVIA by 3.3% in the second quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company's stock worth $325,000 after acquiring an additional 49 shares during the period. Finally, Clear Harbor Asset Management LLC boosted its stake in shares of IQVIA by 1.3% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company's stock worth $941,000 after acquiring an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on IQV. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a report on Thursday. Leerink Partners reiterated an "outperform" rating and set a $248.00 price objective (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Barclays decreased their target price on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Morgan Stanley reduced their price objective on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Finally, Truist Financial lowered their target price on shares of IQVIA from $286.00 to $265.00 and set a "buy" rating on the stock in a research note on Monday, November 4th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $256.50.

IQVIA Price Performance

Shares of NYSE:IQV traded down $0.59 on Friday, reaching $200.84. The company's stock had a trading volume of 513,717 shares, compared to its average volume of 2,104,433. The company has a 50-day simple moving average of $218.67 and a 200 day simple moving average of $226.11. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market cap of $36.45 billion, a P/E ratio of 26.36, a PEG ratio of 2.07 and a beta of 1.51. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.